SINTBILO® :Tafolecimab Injection

In Aug 2023,SINTBILO® (tafolecimab injection) is approved by China's NMPA for the treatment of adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia. Tafolecimab has the advantage of a longer dosing interval compared with other PCSK9 monoclonal antibody agents and a significant decrease in Lp(a). As the first domestic PCSK9 inhibitor approved in China, SINTBILO® (tafolecimab injection) is Innovent's first drug entering the cardiovascular field, as well as the Company's tenth product in its commercial portfolio.